World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
34808
World Ranking
13484
National Ranking
6857

James F. Holland publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James F. Holland sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 579 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James F. Holland D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James F. Holland sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

James F. Holland was affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their research contributions are documented through at least one recent paper published in a notable academic venue.

Their most recent publication, entitled Cardinal Manifestations of Cancer, appeared in 2022 in the volume Holland-Frei Cancer Medicine. This paper has been cited multiple times, indicating engagement by the research community.

Throughout their career, James F. Holland collaborated with several frequent co-authors including:

  • Robert C. Bast
  • John C. Byrd
  • Carlo M. Croce
  • Ernest T. Hawk
  • Fadlo R. Khuri

The primary publication venue where this scientist's work appeared is:

  • Holland-Frei Cancer Medicine

James F. Holland was recognized as a member of the Association of American Physicians. Details regarding the year of this award were not specified.

Best Publications

  • Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

    Lewis R. Silverman;Erin P. Demakos;Bercedis L. Peterson;Alice B. Kornblith

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide

    Charles G. Zubrod;Marvin Schneiderman;Emil Frei;Clyde Brindley

  • Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B

    Lewis R. Silverman;David R. McKenzie;Bercedis L. Peterson;James F. Holland

  • Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

    J Yates;O Glidewell;P Wiernik;Cooper

  • Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

    KR Rai;JF Holland;OJ Glidewell;V Weinberg

  • Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study

    Alice B. Kornblith;James E. Herndon;Lewis R. Silverman;Erin P. Demakos

  • INHIBITION OF CYCLOOXYGENASE-2 SUPPRESSES ANGIOGENESIS AND THE GROWTH OF PROSTATE CANCER IN VIVO

    Xin Hua Liu;Alexander Kirschenbaum;Shen Yao;Richard Lee

  • Diffuse Malignant Mesothelioma: Prospective Evaluation of 69 Patients

    A P Chahinian;T F Pajak;J F Holland;L Norton

  • Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy

    Alice B. Kornblith;James E. Herndon;Raymond B. Weiss;Chunfeng Zhang

  • ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent

    Kiranmai Gumireddy;M.V. Ramana Reddy;Stephen C. Cosenza;R. Boomi Nathan

  • Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

    Yates Jw;Wallace Hj;Ellison Rr;Holland Jf

  • Amputation and adriamycin in primary osteosarcoma

    Engracio P. Cortes;James F. Holland;Jaw J. Wang;Lucius F. Sinks

  • Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

    Yi He Ling;Leonard Liebes;Jian Dong Jiang;James F. Holland

  • Association of Epstein–Barr Virus with Thymic Carcinoma

    Leyvraz S;Henle W;Chahinian Ap;Perlmann C

  • Vincristine treatment of advanced cancer: a cooperative study of 392 cases.

    James F. Holland;Carol Scharlau;Salman Gailani;Melvin J. Krant

  • Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

    Silverman Lr;Holland Jf;Weinberg Rs;Alter Bp

  • Prostaglandin E2 Induces Hypoxia-inducible Factor-1α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line

    Xin Hua Liu;Alexander Kirschenbaum;Min Lu;Shen Yao

  • Experiments with Some Mouse Tumors and Leukemias

    Holland Jf;Guthrie R;Tieckelmann H;Cuddihy R

Frequent Co-Authors

Richard T. Silver
Richard T. Silver Cornell University
Thomas F. Pajak
Thomas F. Pajak RTOG Foundation
Larry Norton
Larry Norton Memorial Sloan Kettering Cancer Center
Morton Coleman
Morton Coleman Cornell University
Jian-Dong Jiang
Jian-Dong Jiang Peking Union Medical College Hospital
Lewis B. Silverman
Lewis B. Silverman Harvard University
Arthur Bank
Arthur Bank Columbia University
Bayard D. Clarkson
Bayard D. Clarkson Memorial Sloan Kettering Cancer Center
Hugh F. Biller
Hugh F. Biller Mount Sinai Hospital
Stanley J. Goldsmith
Stanley J. Goldsmith Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medical careers but seeking alternative or supplementary pathways to the traditional Doctor of Medicine, a range of accredited online programs are available. These degrees can open doors to diverse roles in healthcare—from patient care and management to research and public health.

If you are passionate about nutrition and wellness, consider one of the best online nutrition degree programs. These flexible options allow you to study nutritional science and prepare for in-demand roles such as dietitian or nutritionist.

Aspiring healthcare administrators should explore top cahme-accredited mha programs. A Master of Health Administration can help you build the leadership skills needed for management roles in hospitals and health systems.

Registered Nurses looking to advance their education efficiently can enroll in an rn to bsn with no clinicals program, designed to fit around busy professional schedules.

For nurses holding a master's degree, the shortest post master's dnp program can accelerate your journey to the highest level of clinical nursing practice.

These online degrees provide flexible, reputable options to grow your healthcare career—whether at the bedside, in administration, or in specialized fields.

Best Scientists Citing James F. Holland

Recently Published Articles